Compare · ESTA vs STE
ESTA vs STE
Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESTA and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $21.87B, about 12.0x ESTA ($1.83B).
- ESTA has been more active in the news (9 items in the past 4 weeks vs 4 for STE).
- STE has more recent analyst coverage (17 ratings vs 15 for ESTA).
- Company
- Establishment Labs Holdings Inc.
- STERIS plc (Ireland)
- Price
- -
- -
- Market cap
- $1.83B
- $21.87B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 9
- 4
- Recent ratings
- 15
- 17
Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest ESTA
- Stifel initiated coverage on Establishment Labs with a new price target
- SEC Form 8-K filed by Establishment Labs Holdings Inc.
- Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
- Director Gillin Leslie was granted 262 shares, increasing direct ownership by 1% to 18,856 units (SEC Form 4)
- Director Schutter Edward J was granted 253 shares, increasing direct ownership by 0.14% to 178,205 units (SEC Form 4)
- Director Lewin Nicholas Sheridan was granted 389 shares, increasing direct ownership by 0.04% to 1,080,349 units (SEC Form 4)
- Director Slotkin Bryan was granted 253 shares, increasing direct ownership by 0.77% to 33,052 units (SEC Form 4)
- Director Custin Ann was granted 301 shares, increasing direct ownership by 1% to 24,626 units (SEC Form 4)
- Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
- Chief Executive Officer Caldini Filippo covered exercise/tax liability with 682 shares, decreasing direct ownership by 1% to 48,829 units (SEC Form 4) (tax liability)
Latest STE
- SEC Form 8-K filed by STERIS plc (Ireland)
- Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)
- STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety
- SEC Form 4 filed by STERIS plc (Ireland)
- STERIS to Present at the Morgan Stanley Healthcare Conference
- SEC Form 144 filed by STERIS plc (Ireland)
- SEC Form 4 filed by Director Shapiro Louis
- Director Sohi Mohsen exercised 4,058 units of Ordinary Shares at a strike of $86.23 and sold $956,795 worth of Ordinary Shares (4,058 units at $235.78) (SEC Form 4)
- SEC Form 4 filed by Director Shah Nirav R
- SEC Form 4 filed by Director Martin Paul Edward